Candel Therapeutics (CADL) EPS (Basic) (2020 - 2023)
Historic EPS (Basic) for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$0.38.
- Candel Therapeutics' EPS (Basic) fell 12352.94% to -$0.38 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.3, marking a year-over-year decrease of 10312.5%. This contributed to the annual value of -$1.74 for FY2024, which is 3282.44% down from last year.
- According to the latest figures from Q4 2023, Candel Therapeutics' EPS (Basic) is -$0.38, which was down 12352.94% from -$0.29 recorded in Q3 2023.
- Candel Therapeutics' 5-year EPS (Basic) high stood at $0.51 for Q4 2021, and its period low was -$1.46 during Q2 2021.
- Its 4-year average for EPS (Basic) is -$0.36, with a median of -$0.3 in 2022.
- In the last 5 years, Candel Therapeutics' EPS (Basic) skyrocketed by 15666.67% in 2021 and then crashed by 90000.0% in 2023.
- Candel Therapeutics' EPS (Basic) (Quarter) stood at -$0.9 in 2020, then surged by 156.67% to $0.51 in 2021, then tumbled by 133.33% to -$0.17 in 2022, then plummeted by 123.53% to -$0.38 in 2023.
- Its EPS (Basic) stands at -$0.38 for Q4 2023, versus -$0.29 for Q3 2023 and -$0.33 for Q2 2023.